PDS Biotech holds annual shareholder meeting, quorum reached
PDSB•Annual shareholder meeting results
PDS Biotechnology held its annual stockholder meeting on Aug. 10, 2026.
Stockholders authorized an amendment doubling authorized common stock to 300,000,000 shares from 150,000,000; the charter was otherwise unchanged.
Appointment of KPMG US LLP was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Two Class B directors, Kamil Ali-Jackson and Ilian Iliev, were elected to terms running to the 2029 annual meeting.
